Search Results - "Salgia, R"

Increased μ-opioid receptor expression in metastatic lung cancer by Singleton, P.A., Mirzapoiazova, T., Hasina, R., Salgia, R., Moss, J.

“…We and others have previously demonstrated that the μ-opioid receptor (MOR) is overexpressed in several human malignancies. There is a seven-fold increase in…”
Get full text

Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis by SINGAL, A., VOLK, M. L., WALJEE, A., SALGIA, R., HIGGINS, P., ROGERS, M. A. M., MARRERO, J. A.

“…Summary Background  A majority of studies investigating the accuracy of ultrasound for detecting hepatocellular carcinoma (HCC) do not reflect how this test is…”
Get full text

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer by Carter, C.A., Rajan, A., Keen, C., Szabo, E., Khozin, S., Thomas, A., Brzezniak, C., Guha, U., Doyle, L.A., Steinberg, S.M., Xi, L., Raffeld, M., Tomita, Y., Lee, M.J., Lee, S., Trepel, J.B., Reckamp, K.L., Koehler, S., Gitlitz, B., Salgia, R., Gandara, D., Vokes, E., Giaccone, G.

“…KRAS mutations in NSCLC are associated with a lack of response to epidermal growth factor receptor inhibitors. Selumetinib (AZD6244; ARRY-142886) is an oral…”
Get full text

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1) by Ramalingam, S., Goss, G., Rosell, R., Schmid-Bindert, G., Zaric, B., Andric, Z., Bondarenko, I., Komov, D., Ceric, T., Khuri, F., Samarzija, M., Felip, E., Ciuleanu, T., Hirsh, V., Wehler, T., Spicer, J., Salgia, R., Shapiro, G., Sheldon, E., Teofilovici, F., Vukovic, V., Fennell, D.

“…This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to…”
Get full text

Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer by Jen, J, Lin, L-L, Chen, H-T, Liao, S-Y, Lo, F-Y, Tang, Y-A, Su, W-C, Salgia, R, Hsu, C-L, Huang, H-C, Juan, H-F, Wang, Y-C

“…ZNF322A encoding a classical Cys2His2 zinc finger transcription factor was previously revealed as a potential oncogene in lung cancer patients. However, the…”
Get full text

NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases by Reddy, M M, Fernandes, M S, Salgia, R, Levine, R L, Griffin, J D, Sattler, M

“…Transformation by tyrosine kinase oncogenes (TKOs) in myeloid malignancies, including BCR–ABL in chronic myeloid leukemia, FLT3ITD in acute myeloid leukemia or…”
Get full text

Downstream signalling and specific inhibition of c-MET HGF pathway in small cell lung cancer: implications for tumour invasion by MA, P. C, TRETIAKOVA, M. S, NALLASURA, V, JAGADEESWARAN, R, HUSAIN, A. N, SALGIA, R

“…The c-MET receptor can be overexpressed, amplified, or mutated in solid tumours including small cell lung cancer (SCLC). In c-MET-overexpressing SCLC cell line…”
Get full text

Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer by Jen, J, Lin, L-L, Lo, F-Y, Chen, H-T, Liao, S-Y, Tang, Y-A, Su, W-C, Salgia, R, Hsu, C-L, Huang, H-C, Juan, H-F, Wang, Y-C

“…This corrects the article DOI: 10.1038/onc.2015.296…”
Get full text

Tumor Biomarker Evaluation of 6785 Patients for Combination Treatment Strategies in NSCLC by Feldman, R, Xiu, J, Salgia, R

Get full text

Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer by Jen, J, Lin, L-L, Lo, F-Y, Chen, H-T, Liao, S-Y, Tang, Y-A, Su, W-C, Salgia, R, Hsu, C-L, Huang, H-C, Juan, H-F, Wang, Y-C

“…This corrects the article DOI: 10.1038/onc.2015.296…”
Get full text

Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature by Lukas, R. V., Mata-Machado, N. A., Nicholas, M. K., Salgia, R., Antic, T., Villaflor, V. M.

“…Summary The aim of this study was to more clearly define the clinical course of leptomeningeal carcinomatosis due to esophageal cancer. A single institution…”
Get full text

Female Presidents in American Gastroenterology Societies: An Upward Trend by Mansour, M.R., Denha, E.J., Rida, A.M., Meram, T.D., Abushukur, Y., Salgia, R.J.

Get full text

Unique Pattern of Metastasis to the Adnexa in ALK Rearranged Non-Small Cell Lung Cancer by West, A.H, Yamada, S.D, MacMahon, H, Ali, S.M, Lukas, R.V, Salgia, R

Get full text

Efficacy of MET Inhibitors in NSCLC With CBL Alterations by Tan, Y.C, Rolle, C, Zhu, L, Srivastava, M.K, Sharma, S, Salgia, R

Get full text

Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance) by Urbanic, J.J, Wang, X, Bogart, J.A, Stinchcombe, T, Hodgson, L, Schild, S.E, Bazhenova, L, Salgia, R, Vokes, E.E

Get full text

Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab by Iida, M, Bahrar, H, Brand, T, Pearson, H, Coan, J, Orbuch, R, Flanigan, B, Swick, A, Prabakaran, P, Lantto, J, Horak, I, Kragh, M, Salgia, R, Kimple, R, Wheeler, D

“…Cetuximab, an antibody against the Epidermal Growth Factor Receptor (EGFR) has shown efficacy in treating head and neck squamous cell carcinoma (HNSCC),…”
Get full text

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer by Chiappori, A A, Schreeder, M T, Moezi, M M, Stephenson, J J, Blakely, J, Salgia, R, Chu, Q S, Ross, H J, Subramaniam, D S, Schnyder, J, Berger, M S

“…Background: Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate the safety of obatoclax, a…”
Get full text

Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer by Ferguson, B.D, Kanteti, R.S, Tan, Y, Liu, R, Gayed, M.J, Vokes, E.E, Ferguson, M.K, Iafrate, A.J, Gill, P.S, Salgia, R

Get full text

489 Development and clinical validation of a quantitative mass spectrometric assay for PD-L1 protein in FFPE NSCLC samples by An, E, Liao, W, Thyparambil, S, Rodriguez, J, Salgia, R, Wistuba, I, Burrows, J, Hembrough, T

Get full text

Molecular abnormalities in lung cancer by Salgia, R, Skarin, A T

“…To review several recently described molecular abnormalities in lung cancer and discuss their potential diagnostic and therapeutic relevance. Articles were…”
Get more information